X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
First subject has been enrolled in Sentien's Phase 1/2 study of SBI-101 trial. SBI-101 is a cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome and acute kidney injury (AKI) requiring renal replacement therapy.
Lead Product(s): Allogeneic mesenchymal stromal cells
Therapeutic Area: Infections and Infectious Diseases Product Name: SBI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).
Lead Product(s): Mesenchymal stromal cells
Therapeutic Area: Infections and Infectious Diseases Product Name: SBI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
